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ABSTRACT
Aims/Introduction: We compared clinical characteristics in patients with type 2
diabetes for whom different antihyperglycemic agents were prescribed as monotherapy
or combination therapy by diabetes specialists in Japan.
Materials and Methods: Prescription data for 2005, 2008 and 2011 from diabetes
specialists’ patient registries identified variables related to prescription of different antihy-
perglycemic agents.
Results: A total of 33,251 prescriptions in 2005, 25,119 in 2008 and 20,631 in 2011 were
analyzed. Prescribing insulin was related to younger age, long duration of diabetes and
glycated hemoglobin (HbA1c) ≥8.0%, but was negatively associated with obesity. Prescrib-
ing sulfonylureas was related to older age and long duration of diabetes, but not to obe-
sity. Use of biguanides was related to younger age, short duration of diabetes and
obesity, but was negatively associated with HbA1c ≥8.0%. A short duration of diabetes
and HbA1c ≥8.0% were associated with use of a DPP-4 inhibitor, but not with obesity.
Prescribing GLP-1 receptor agonists was related to younger age, obesity and HbA1c
≥8.0%. Odds ratios for each antihyperglycemic combination therapy were determined
based on the characteristics of each included antihyperglycemic agent.
Conclusions: These results could be expected to reflect in part the consensus of dia-
betes specialists, and might provide guidance regarding pharmacotherapy in the clinical
setting.
INTRODUCTION
Eight different drug classes are currently approved for treat-
ment of hyperglycemia in patients with type 2 diabetes in
Japan, with several new drugs having been developed during
the past decade1. The choice of medication should depend on
individual patient factors while strictly adhering to clinical
guidelines and recommendations1,2. Needless to say, diabetes
specialists are expected to choose antihyperglycemic medica-
tions in consideration of factors that inﬂuence the overall health
of each patient. However, there has been little clariﬁcation of
the relationship between patient factors and the antihyper-
glycemic agents that have been prescribed by diabetes specialists
for patients with type 2 diabetes.
Although metformin is recommended as ﬁrst-line therapy
for type 2 diabetes2, approximately 35% of patients initiating
the use of an oral hypoglycemic drug did not receive the rec-
ommended initial therapy with metformin in the USA3. ThisReceived 9 February 2015; revised 24 May 2015; accepted 16 June 2015
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suggests that physicians considered a wide range of other
factors, such as patient characteristics and non-clinical issues, in
choosing antihyperglycemic medications for patients with
type 2 diabetes4. Grant et al.4 reported that a survey of both
diabetes specialists and generalists showed that many issues
were considered when choosing an initial prescription of an
antihyperglycemic medication, such as overall assessment of
patients’ health and comorbid conditions, glycemic control,
adherence behavior and bodyweight in addition to the physi-
cian’s usual practice. Furthermore, those choices were more
affected by patient factors, such as glycemic control and body-
weight, than by experts’ guidelines or hospital algorithms4.
Therefore, investigating those relationships over a period of
time using data from a large group of diabetes specialists could
reveal why physicians do not choose metformin as the ﬁrst-line
drug, and determine the common factors involved in prescrip-
tion of antihyperglycemic drugs among diabetes specialists.
The Japan Diabetes Clinical Data Management Study Group
(JDDM) is one of the largest Japanese diabetes cohorts consist-
ing of more than 100 leading clinical diabetologists in 98 facili-
ties, and has provided information on characteristics of patients
with type 2 diabetes as well as antihyperglycemic prescription
trends in Japan5–8. In addition, the choices of antihyperglycemic
medications have depended on physicians’ considerations, as in
Japan therapeutic guidelines have not speciﬁed the ﬁrst-line or
combination of antihyperglycemic agents to be used. Asian,
including Japanese, patients with type 2 diabetes tend to be
characterized more by impaired insulin secretion than by
increased insulin resistance compared with Caucasians1,9–11.
Furthermore, there has not been sufﬁcient clinical data to deter-
mine the most appropriate ﬁrst-line or second-line antihyper-
glycemic agent in Japan. Therefore, using JDDM data, we
examined the clinical characteristics of type 2 diabetic patients
among whom different antihyperglycemic agents were pre-
scribed as monotherapy or combination therapy by specialists.
METHODS
Data were extracted by software (CoDic; Novo Nordisk Pharm
Ltd., Tokyo, Japan) from the JDDM on patients prescribed anti-
hyperglycemic agents in 2005, 2008 and 2011. The details of the
JDDM and CoDic were described elsewhere5–8. We included as
participants individuals who were aged 20 years or older who
underwent medical treatment in outpatient clinics for type 2 dia-
betes. Prospective participants included 33,820 patients from
2005, 44,973 patients from 2008 and 55,881 patients from 2011.
We excluded 13,189 patients from 2005, 19,854 patients from
2008 and 22,630 patients from 2011 because of incomplete data
or not having been prescribed antidiabetic medicines. This left
20,631 patients from 2005, 25,119 patients from 2008 and
33,251 from 2011 for analysis. The present study was approved
by the ethics committee of the JDDM, and informed consent
was obtained from all patients at each participating institute in
accordance with the Guidelines for Epidemiological Studies of
the Ministry of Health, Labor and Welfare of Japan.
Baseline examinations
We analyzed data collected on study patients in January for
each year; however, when data from January were not available
for a patient, data from February or March were used. The
types of therapy were divided into eight categories: insulin, sul-
fonylureas, biguanides, alpha-glucosidase inhibitors (a-GI), thia-
zolidinediones, dipeptidyl peptidase-4 inhibitors (DPP-4I),
glinides and glucagon-like peptide-1 receptor agonists (GLP-1).
For the calculation of rates of prescription of each type of med-
ication, we calculated the number of patients prescribed each
speciﬁc antihyperglycemic medication divided by the total num-
ber of patients receiving antidiabetic therapy for each year. Gly-
cated hemoglobin (HbA1c) was measured by high-performance
liquid chromatography using either the ADAMS A1c (Arkray,
Kyoto, Japan) or HLC-723 (Tosoh Corp., Tokyo, Japan).
HbA1c was converted from the Japanese Diabetes Society
values into National Glycohemoglobin Standardization Program
equivalent values12. Hypertension was deﬁned as systolic blood
pressure ≥140 mmHg and/or diastolic blood pressure
≥90 mmHg or the current use of antihypertensive agents.
Statistical analysis
Categorical variables were expressed as numerals and percent-
ages, and were compared using the Cochran–Armitage test.
Continuous variables were expressed as mean – standard devia-
tion, and were compared using one-way ANOVA tests for com-
parisons of each group according to year. Logistic regression
analyses were carried out to identify variables related to each
antihyperglycemic prescribed for both monotherapy and combi-
nation therapy. Covariates included age (<50, 50–64 and
≥65 years), sex, duration of diabetes (<10 and ≥10 years), body
mass index (BMI; <25.0 and ≥25.0 kg/m2), hypertension and
HbA1c (<8.0 and ≥8.0% [64 mmol/mol]). All statistical analy-
ses were carried out by SPSS (version 18.0; SPSS, Chicago, IL,
USA), and statistical signiﬁcance was considered for P < 0.05.
RESULTS
Table 1 lists the participants’ baseline characteristics according
to the study year. Except for the prevalence of hypertension
and use of insulin therapy, there were signiﬁcant differences
among the years. Tables 2 and S1–S3 show the characteristics
of study participants receiving each antihyperglycemic medica-
tion as monotherapy or combination therapy. Participants who
were prescribed insulin were on the whole younger, had a
lower BMI, a longer duration of diabetes, and worse glycemic
control while those who were given sulfonylurea were older,
had a lower BMI and a longer duration of diabetes. Participants
who were prescribed biguanides were younger, had a higher
BMI and a shorter duration of diabetes, whereas those who
were given thiazolidinediones had a higher BMI. Participants
who were prescribed DPP-4I had a lower BMI and a shorter
duration of diabetes, and those who were prescribed GLP-1
were younger, had a higher BMI and worse glycemic control.
Those who were prescribed a-GI or glinides were older, had a
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lower BMI and better glycemic control. Tables 3 and 4, and
Tables S4 and S5 show the results of logistic regression analyses
for each year studied. Figure 1 shows the schema of odds ratios
for explanatory variables in logistic regression analysis for the
selected antihyperglycemic medications as monotherapy in
2011. Prescribing insulin was related to younger age, long dura-
tion of diabetes and HbA1c ≥8.0% (64 mmol/mol), but was
negatively associated with obesity. The use of sulfonylureas was
associated with older age and long duration of diabetes, but
was negatively associated with obesity. Prescribing biguanides
was related to younger age, short duration of diabetes, obesity
and hypertension, but was negatively associated with HbA1c
≥8.0% (64 mmol/mol). The use of DPP-4I was related to a
short duration of diabetes and HbA1c ≥8.0% (64 mmol/mol),
but was negatively associated with obesity. Finally, prescribing
GLP-1 was related to younger age, obesity and HbA1c ≥8.0%
(64 mmol/mol). Odds ratios for each antihyperglycemic combi-
nation therapy were determined based on the characteristics of
each agent comprising the combination therapy.
DISCUSSION
As far as we know, this is the ﬁrst study to investigate the rela-
tionships between patient factors and antihyperglycemic pre-
scriptions provided by diabetes specialists for patients with
type 2 diabetes over a period of time in Japan. We found
considerable differences in characteristics among patients who
were prescribed various antihyperglycemic medications by
diabetes specialists. These ﬁndings might partially reﬂect the
consensus of specialists as to what agents would be most suit-
able for patients with particular characteristics. This information
would be useful for developing algorithms for pharmacotherapy
based on specialists’ prescriptions for type 2 diabetes.
Japan is a developed country that has provided universal
health coverage, which allows virtually all persons to have
access to curative services, including those in specialty outpa-
tient clinics, at an affordable cost13. Furthermore, this Japanese
public insurance allows doctors to prescribe antihyperglycemic
medications with comparative ease without worrying about
insurance regulations, such as the forced use of generics13.
Therefore, we believe that those differences in the characteristics
of patients prescribed each antihyperglycemic medication by
Japanese diabetes specialists reﬂect their opinions of the suit-
ability of speciﬁc agents for speciﬁc patients.
Trends in prescriptions for antihyperglycemic agents were
substantially examined in USA, UK and Japan8,14–16. However,
to the best of our knowledge, no study has investigated the
relationships between the characteristics of patients and eight
classes of antihyperglycemic agents that were prescribed by
Table 1 | Characteristics of study participants according to data acquired from 3 years
Sample characteristic 2011 2008 2005 P-value
No. patients (n) 33,251 25,119 20,631
Age (years) 62 – 12 62 – 12 61 – 12 <0.001
Age <50 years (%) 4,966 (15) 3,733 (15) 3,170 (15) <0.219
Age 50–64 years (%) 13,251 (40) 10,589 (42) 9,138 (44) <0.001
Age ≥65 years (%) 15,034 (45) 10,797 (43) 8,323 (40) <0.001
Male/female 20,503/12,748 15,292/9,827 12,361/8,270 <0.001
BMI (kg/m2) 24.7 – 4.3 24.5 – 4.2 24.1 – 3.8 <0.001
Duration of diabetes (years) 12.6 – 9.1 11.8 – 8.8 12.3 – 11.3 <0.001
Hypertension, n (%) 18,532 (56) 13,685 (54) 11,420 (55) 0.212
Systolic blood pressure (mmHg) 128 – 16 129 – 18 131 – 17 <0.001
Diastolic blood pressure (mmHg) 73 – 11 74 – 11 76 – 11 <0.001
HbA1c, % (NGSP) 7.4 – 1.2 7.5 – 1.3 7.7 – 1.4 <0.001
HbA1c, mmol/mol (IFCC) 57 – 13 58 – 14 61 – 15
Any insulin therapy 10,804 (32) 8,441 (34) 6,845 (33) 0.051
Insulin monotherapy 5,880 (18) 5,448 (22) 4,479 (22) <0.001
Insulin plus any OAD 4,924 (15) 2,933 (12) 2,366 (11) <0.001
Any OAD therapy 27,371 (82) 19,671 (78) 16,152 (78) <0.001
OAD monotherapy 8,575 (26) 7,580 (30) 7,043 (34) <0.001
Sulfonylureas 3,240 (9.7) 4,141 (16) 4,477 (23) <0.001
Biguanides 2,357 (7.1) 1,336 (5.3) 802 (3.9) <0.001
Thiazolidinediones 670 (2.0) 617 (2.5) 218 (1.1) <0.001
DPP-4 inhibitors 538 (1.6) – – –
a-Glucosidase inhibitors 825 (2.5) 687 (2.7) 914 (4.4) <0.001
Glinides 873 (2.6) 799 (3.2) 632 (3.1) <0.001
GLP-1 analogs monotherapy 52 (0.2) – – –
BMI, body mass index; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1 receptor agonists; HbA1c, glycated hemoglobin; IFCC,
International Federation of Clinical Chemistry; OAD, oral antidiabetic drug; NGSP, National Glycohemoglobin Standardization Program.
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diabetes specialists over a period of time. Therefore, physicians
have had few clues as to what diabetes specialists considered
when prescribing antihyperglycemic medications. Grant et al.4
investigated the relationships among the choices of a patient’s
initial antihyperglycemic medication; the use of thiazolidine-
diones (glitazones), which are often considered second-line
agents; the initiation of insulin; and patient factors. However,
those investigators did not adjust their results by detailed
patient factors, such as the HbA1c level, BMI and duration of
diabetes, which could affect which antihyperglycemic is pre-
scribed. The present results showed the relationships between
various patient characteristics and eight classes of antihyper-
glycemic agents prescribed by diabetes specialists over a period
of time.
Physicians have a low to moderate rate of adherence to clini-
cal recommendations for treating type 2 diabetes17,18. Desai
et al.3 showed that one-third of patients initiating oral antihy-
perglycemic medications did not receive the recommended ini-
tial therapy with metformin. However, those results might have
reﬂected consideration of patient factors and non-clinical issues.
In other words, physicians, especially diabetes specialists, recog-
nized the importance of patient-centered care, which was
emphasized in the American Diabetes Association the Euro-
pean Association for the Study of Diabetes consensus recom-
mendations regarding metformin3. Although physicians
basically strongly adhere to consensus statements, they might
choose other antihyperglycemic medications because of individ-
ual patient factors, such as age, duration of diabetes, contraindi-
cations or social issues. Our ﬁndings might reﬂect in part the
consensus of specialists as to the suitability of speciﬁc agents
for patients with speciﬁc characteristics, which is not speciﬁed
in the current consensus recommendations2.
Prescribing insulin is associated with a long duration of dia-
betes and poor glycemic control, but not obesity. Compared
with insulin resistance, impaired insulin secretion had a greater
impact on the background of type 2 diabetes in a Japanese
population9–11. The lack of association between older age and
insulin prescription could be due to difﬁculty in accurately
injecting insulin in among older adults; also dementia and
insufﬁcient social support might play a role. The characteristics
of patients receiving sulfonylureas were similar to those pre-
scribed insulin with the exception of age. Physicians might
choose sulfonylureas rather than insulin, because sulfonylureas
can be administered orally.
Prescribing biguanides was found to be related to a younger
age, short duration of diabetes and obesity. Although bigua-
nides are not deﬁned as a ﬁrst-line antihyperglycemic agent in
Japan, the present results are consistent with a previous study19,
and also with the consensus statement of the American Dia-
betes Association and the European Association for the Study
of Diabetes2. It is generally considered that chronic biguanides
use is weight-neutral20, and does not increase the risk of hypo-
glycemia21. Biguanides can cause lactic acidosis, and avoiding
its use is advised in patients at risk for lactic acidosis, such asTa
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older patients and those with advanced renal insufﬁciency22.
The present study results might support the opinion that Japa-
nese diabetes specialists considered the wide range of indica-
tions for biguanides. The major therapeutic effect of
thiazolidinediones for type 2 diabetes is improvement in insulin
sensitivity23. In the present study, prescribing thiazolidinediones
was related to obesity. However, a reverse association could not
be ruled out, as it was previously shown that thiazolidinediones
were associated with increased bodyweight24. Therefore, body-
weight in patients taking thiazolidinediones might have
increased after administration.
The DPP-4I prescription rate has dramatically increased in
Japan8,15. Furthermore, a recent meta-analysis showed that
DPP-4I exhibited better glucose-lowering efﬁcacy in studies con-
sisting of ≥50% Asians compared with studies having <50%
Asians25. In the present study, prescribing DPP-4I was related
to a short duration of diabetes and poor glycemic control, but
was negatively associated with obesity. The mechanism of DPP-
4I is to increase incretin levels, leading to increased insulin
secretion26. The present results might indicate that Japanese dia-
betes specialists considered that particular mechanism of DPP-
4I in treating type 2 diabetes. A previous study showed that
patients with type 2 diabetes who were prescribed sitagliptin
regimens in clinical practice were older than patients receiving
non-sitagliptin regimens27. These discrepancies in the results on
patients’ background related to DPP-4I prescription could result
from statistical differences in the two studies. GLP-1 was
reported to reduce bodyweight and be effective in obese
patients28. Our results were consistent with those previous
studies28. We found that Japanese diabetes specialists chose
GLP-1 for younger obese patients with type 2 diabetes, suggest-
ing concerns over weight loss and improvement in glycemic
control in prescribing GLP-1. We did not have data on combi-
nation therapy with GLP-1 and other antihyperglycemic agents
except for sulfonylureas, because combination therapy was not
allowed in Japan in 2011.
Both glinides and a-GI suppress rises in postprandial glu-
cose. Glinides enhanced early insulin secretion29, whereas a-GI
delayed the digestion of ingested carbohydrates30. Postprandial
hyperglycemia characterizes early stages of type 2 diabetes31,32.
The present results were compatible with the hypothesis that
Japanese diabetes specialists might choose both glinides and a-
GI for early type 2 diabetes. The relationship between a-GI
prescription and long duration of diabetes compared with glin-
ides might be as a result of continued use, whereas a physician
could change glinides to another antihyperglycemic agent when
Table 4 | Odds ratios for explanatory variables in logistic regressions for selected diabetes drug therapies in 2011
INS INS + S INS + B INS + T INS + a-GI INS + glinides INS + S + B
n 5,880 511 1,169 209 733 112 570
Age 50–64 vs <50 years 0.31 (0.29–0.34) 1.50 (1.07–2.10) 0.88 (0.75–1.04) 0.97 (0.64–1.46) 1.25 (0.94–1.65) 0.78 (0.42–1.45) 1.34 (1.03–1.73)
Age ≥65 vs <50 years 0.30 (0.27–0.32) 1.91 (1.37–2.67) 0.61 (0.51–0.73) 1.16 (0.76–1.76) 1.95 (1.48–2.57) 1.03 (0.56–1.87) 1.06 (0.80–1.40)
Sex (male) 0.70 (0.66–0.74) 0.83 (0.69–0.99) 0.71 (0.63–0.79) 0.84 (0.64–1.11) 0.80 (0.69–0.93) 0.66 (0.45–0.96) 0.90 (0.76–1.06)
Duration of diabetes
≥10 years
1.94 (1.83–2.07) 2.40 (1.95–2.97) 1.81 (1.59–2.06) 1.41 (1.05–1.88) 1.47 (1.25–1.73) 1.35 (0.91–2.00) 2.20 (1.82–2.66)
BMI ≥25 (kg/m2) 0.46 (0.43–0.49) 0.80 (0.66–0.97) 2.02 (1.78–2.29) 2.55 (1.90–3.44) 0.58 (0.50–0.69) 0.42 (0.26–0.66) 1.82 (1.53–2.17)
Hypertension 0.91 (0.86–0.97) 1.14 (0.95–1.37) 1.26 (1.11–1.43) 1.05 (0.79–1.41) 1.13 (0.97–1.32) 1.00 (0.68–1.47) 1.17 (0.98–1.40)
HbA1c ≥8.0%
(64 mmol/mol)
1.65 (1.54–1.76) 2.28 (1.89–2.75) 2.43 (2.15–2.75) 2.11 (1.58–2.81) 1.50 (1.27–1.78) 1.03 (0.64–1.65) 2.61 (2.20–3.11)
INS + S + T INS + S
+ a-GI
INS + B
+ T
INS + B + a-GI INS + B
+ glinides
INS + T
+ a-GI
INS + a-GI
+ glinides
n 113 237 180 236 35 89 41
Age 50–64 vs <50 years 2.97 (1.40–6.31) 2.29 (1.24–4.24) 1.13 (0.76–1.68) 1.11 (0.75–1.67) 1.35 (0.44–4.18) 1.03 (0.52–2.05) 3.47 (0.44–27.1)
Age ≥65 vs <50 years 2.95 (1.36–6.40) 3.73 (2.03–6.85) 0.68 (0.43–1.08) 1.19 (0.79–1.80) 1.38 (0.43–4.39) 1.74 (0.89–3.43) 6.91 (0.91–52.2)
Sex (male) 1.06 (0.72–1.56) 1.12 (0.86–1.46) 0.69 (0.51–0.92) 0.75 (0.58–0.97) 0.68 (0.35–1.33) 1.45 (0.93–2.29) 1.06 (0.57–2.00)
Duration of diabetes
≥10 years
1.75 (1.16–2.64) 1.84 (1.37–2.47) 1.79 (1.31–2.46) 1.45 (1.10–1.92) 1.44 (0.70–2.95) 0.95 (0.62–1.47) 1.24 (0.64–2.40)
BMI ≥25 (kg/m2) 1.76 (1.20–2.59) 0.57 (0.42–0.77) 6.58 (4.41–9.83) 1.43 (1.09–1.87) 0.85 (0.42–1.71) 1.69 (1.10–2.61) 0.28 (0.12–0.67)
Hypertension 0.72 (0.49–1.05) 1.03 (0.79–1.35) 0.81 (0.60–1.10) 1.16 (0.89–1.53) 1.27 (0.62–2.58) 0.85 (0.55–1.31) 1.18 (0.62–2.24)
HbA1c ≥8.0%
(64 mmol/mol)
2.70 (1.84–3.96) 2.01 (1.51–2.66) 2.07 (1.52–2.81) 2.37 (1.81–3.10) 2.46 (1.22–4.95) 1.28 (0.78–2.09) 1.02 (0.45–2.33)
a-GI, alpha-glucosidase inhibitors; B, biguanides; BMI, body mass index; D, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1 receptor
agonists; HbA1c, glycated hemoglobin; hypertension, systolic blood pressure ≥140 and/or diastolic blood pressure ≥90 or treatment; S, sulfonylureas;
T, thiazolidinediones.
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glycemic control worsens or is not adequate. Further studies
are required to clarify those differences.
Several limitations need be addressed regarding the present
study. First, our analysis included both patients who had just
started an antihyperglycemic agent and those who had received
an antihyperglycemic agent for various periods of time. Further-
more, we did not analyze the combination therapies in any speci-
ﬁc order of prescription. Further studies are required to assess the
intention of specialists by analyzing separately patients newly pre-
scribed an antihyperglycemic agent or only patients whose pre-
scriptions had been changed in outpatient care. Second, the
present study had numerous missing data. Also, we could not
obtain information on the presence or absence of diabetes com-
plications, dementia, renal failure, liver disease, cardiovascular
disease and other comorbidities because of imperfect data in the
CoDic database. Consensus recommendations emphasize consid-
ering patient factors, such as comorbidities, vascular complica-
tions and life expectancy2. Social support and patient adherence
also inﬂuenced the choice of antihyperglycemic medication2,19.
Therefore, further studies are necessary to clarify the relationships
between the prescription of each antihyperglycemic medication
and characteristics of patients including those important factors
and the detailed age groups. Third, the study was cross-sectional
and can never prove causality. For example, the relationship
between BMI or glycemic control and an antihyperglycemic pre-
scription should be interpreted cautiously because of possible
reverse associations. Therefore, no deﬁnitive conclusions can be
drawn from our results. Fourth, the prescription periods were too
short to assess a relationship between the antihyperglycemic pre-
scription and characteristics of participants with regard to DPP-
4I or GLP-1. Conﬁrmation of these results over long periods of
time and with an adequate number of patients is required. Fifth,
selection bias by physicians should be considered. However, the
trends in prescribing DPP-4I in the present JDDM cohort can be
considered similar to results of another Japanese study15. In con-
clusion, as far as we know, this is the ﬁrst study to investigate the
relationships between patient factors and antihyperglycemic pre-
scriptions provided by diabetes specialists for patients with type 2
diabetes over a period of time in Japan. Our results showed con-
siderable differences in characteristics among patients who were
prescribed various antihyperglycemic medications by diabetes
specialists. These differences might partially reﬂect the consensus
Age <50 Age 50–64 Age ≥65 Male sex Duration of
diabetes≥10 years
HbA1c ≥8.0%BMI ≥25 HT
INS
Age <50 Age 50–64 Age ≥65 Male sex
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
Age <50 Age 50–64 Age ≥65 Male sex
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
Age <50 Age 50–64 Age ≥65 Male sex
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
Age <50 Age 50–64 Age ≥65 Male sex Duration of
diabetes≥10 years
HbA1c ≥8.0%BMI ≥25 HT Age <50 Age 50–64 Age ≥65 Male sex
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
Age <50 Age 50–64 Age ≥65 Male sex
DPP-4I GLP-1
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
Age <50 Age 50–64 Age ≥65 Male sex
Duration of
diabetes≥10 years HbA1c ≥8.0%BMI ≥25 HT
SU
BG TZD
α-GI Glinides
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1 | Schema of odds ratios for explanatory variables in logistic regression analysis for selected antihyperglicemic medications: (a) insulin, (b)
sulfonylurea, (c) biguanides, (d) thiazolidinediones, (e) alpha-glucosidase inhibitors (a-GI), (f) glinides, (g) dipeptidyl peptidase-4 inhibitors (DPP-4I) and
(h) glucagon-like peptide-1 receptor agonists (GLP-1) as monotherapy in 2011. Each dot representing age <50 indicates an odds ratio of 1.00. The
size of the dots reflects the odds ratio for each explanatory variable. BG, biguanides; BMI, body mass index; HbA1c, glycated hemoglobin; HT,
hypertension; INS, insulin; SU, sulfonylurea; TDZ, thiazolidinediones.
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of specialists as to what agents would be most suitable for patients
with particular characteristics. This information therefore could
provide guidance regarding pharmacotherapy in the clinical
setting.
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